Calcitriol for Secondary Hyperparathyroidism in CKD

Rationale for Calcitriol Use in CKD

Secondary hyperparathyroidism develops early in CKD (Stage 3) with elevated serum intact PTH levels, even when plasma 1,25(OH)₂D₃ levels are normal or in the lower range of normal, according to the American Journal of Kidney Diseases 1
This "inappropriately normal" 1,25(OH)₂D₃ level contributes to defective feedback suppression of pre-PTH synthesis in the parathyroid glands, resulting in increased PTH secretion, as reported by the American Journal of Kidney Diseases 2
Bone biopsies in these patients show histomorphometric features of hyperparathyroid bone disease despite only modest elevations of intact PTH, as found by the American Journal of Kidney Diseases 3

The American Journal of Kidney Diseases recommends starting with oral calcitriol 0.25 μg/day, occasionally increasing up to 0.5 μg/day for non-dialysis CKD patients (Stage 3-4) 1
For dialysis patients (Stage 5), hemodialysis with intermittent intravenous administration is more effective than daily oral calcitriol for lowering serum PTH levels, according to the American Journal of Kidney Diseases 4

The American Journal of Kidney Diseases suggests monitoring serum calcium and phosphorus at least every month for the first 3 months after initiation, then every 3 months thereafter 6
Target PTH range for dialysis patients is 150-300 pg/mL (16.5-33.0 pmol/L), as recommended by the American Journal of Kidney Diseases 4

Preliminary evidence from the American Journal of Kidney Diseases suggests that patients who started calcitriol when creatinine clearance exceeded 30 mL/min/1.73 m² had normal bone histology when they reached Stage 5 CKD 1

Paricalcitol and doxercalciferol may be considered in patients with elevated calcium or phosphorus levels, according to the American Journal of Kidney Diseases 4

With low doses of calcitriol (≤0.25 μg/day) or alfacalcidol (<0.5 μg/day), progressive loss of kidney function did not differ from placebo-treated patients, as reported by the American Journal of Kidney Diseases 1
Hypercalcemia must be avoided as it may cause transient or long-lasting deterioration of kidney function, according to the American Journal of Kidney Diseases 1
Careful monitoring of serum calcium, phosphorus, and intact PTH is essential, as recommended by the American Journal of Kidney Diseases 2